Clinical Trial Update: A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of TAK-662 in Japanese patients with congenital protein C deficiency has completed, with results posted in January 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Protein Deficiency

Drugs mentioned

• TAK-662 (human protein C concentrate)

Snippet

Sponsor: Takeda | Conditions: Congenital Protein C Deficiency | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-01-05